NCT07182708尚未招募2 期
High-dose Firmonertinib Combined With Bevacizumab as Neoadjuvant Therapy in Stage II-IIIB, Resectable, EGFR-mutated Non-small Cell Lung Cancer Patients: A Single-arm, Multi-center, Open-label Phase II Clinical Study
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2025年10月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- pathological Complete Response(pCR) rate
研究概览
简要总结
This is a Phase II, single-arm, open-label, multicenter clinical study aimed at evaluating the efficacy and safety of Firmonertinib 160 mg combined with Bevacizumab as neoadjuvant therapy in patients with resectable stage II-IIIB Epidermal Growth Factor Receptor(EGFR)-mutated non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged ≥18 years.
- •Histologically/cytologically confirmed primary non-small cell lung cancer within 60 days prior to the study.
- •Stage II-IIIB disease evaluated by endobronchial ultrasound guided tranbronchial needle aspiration(EBUS-TBNA), mediastinoscopy, or Positron Emission Tomography/Computed Tomography (PET/CT), with lesions planned for radical resection after neoadjuvant therapy.
- •EGFR mutation-positive confirmed by local laboratory testing of tissue or blood samples.
- •Presence of at least one measurable lesion, with a baseline Computed Tomography (CT) scan showing the longest diameter ≥10 mm (except for lymph nodes, which must have a short axis ≥15 mm), and suitable for accurate repeated measurements.
- •ECOG performance status score of 0-1, with no deterioration within 2 weeks prior to the first dose administration.
- •Female patients should adopt fully effective contraceptive measures, must not be breastfeeding, and have a negative pregnancy test before the first administration of the study drug; or female patients must meet the following criteria at screening to confirm the absence of reproductive potential:
- •Postmenopausal, defined as age greater than 50 years and amenorrhea for at least 12 months after cessation of all exogenous hormonal therapies.
- •For women under 50 years of age, they are considered postmenopausal if they have not had a menstrual period for 12 months or more after stopping exogenous hormone therapy, and their luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are within the postmenopausal range.
- •Documented irreversible sterilization procedures, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, excluding tubal ligation.
- •Male patients should be willing to use barrier contraception, i.e., condoms.
排除标准
- •Presence of small cell lung cancer or mixed pathological types of NSCLC. EGFR exon 20 insertion mutation detected by genetic testing.
- •Exposure to any other antitumor therapy prior to enrollment, including perioperative radiotherapy.
- •The patient is in pregnancy or lactation.
- •History of other malignant tumors, or currently combined with other malignant tumors (except for malignancies that have undergone radical surgery with no recurrence within 5 years post-operation, such as cervical carcinoma in situ, basal cell carcinoma of the skin, and papillary thyroid carcinoma, etc.).
- •Presence of severe or uncontrolled systemic diseases requiring treatment, which the investigator deems unsuitable for trial participation, including hypertension, diabetes mellitus, chronic heart failure (New York Heart Association, NYHA Class III-IV), unstable angina, myocardial infarction within the past year, etc.
- •Severe gastrointestinal dysfunction, diseases, or clinical conditions that may affect the intake, transport, or absorption of the study drug, such as inability to take oral medications, uncontrollable nausea and vomiting, extensive gastrointestinal resection history, etc.
- •Any of the following laboratory tests indicate insufficient bone marrow reserve or organ reserve function.
- •Absolute neutrophil count <1.5×10^9/L
- •Platelet count <100×10^9/L
- •Hemoglobin <90 g/L
- •Alanine aminotransferase (ALT) >2.5×upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) >2.5×ULN
- •Total bilirubin >1.5×ULN or >3×ULN in cases of Gilbert's syndrome (unconjugated hyperbilirubinemia)
- •Known or suspected allergy to almonertinib mesylate, bevacizumab, or any other component of their formulations, or patients with other contraindications.
- •If the patient cannot comply with the study procedures, restrictions, and requirements, or if the investigator deems the patient ineligible or unsuitable for participation in the study for any other reason.
- •Patients currently or previously enrolled in any other anti-tumor clinical studies.
研究组 & 干预措施
Neoadjuvant therapy
Experimental
干预措施: Firmonertinib Mesilate Tablets (Drug)
Neoadjuvant therapy
Experimental
干预措施: Bevacizumab injection (Drug)
结局指标
主要结局
pathological Complete Response(pCR) rate
时间窗: Within 24 hours after surgical resection
Defined as the proportion of patients with no residual viable tumor cells in the primary lesion, as assessed by central laboratory pathologists after surgical resection.
次要结局
- Major pathological response (MPR) rate(Within 7 days after surgical resection)
- Radical resection rate(Within 7 days after surgical resection)
- Lymph node downstaging rate(Within 7 days after completion of neoadjuvant therapy and within 7 days after surgical resection)
- Pathological positive lymph node conversion rate(Within 7 days after completion of neoadjuvant therapy and within 7 days after surgical resection)
- Objective response rate (ORR) by investigator(Approximately 9 weeks following the first dose of Firmonertinib)
- Event-free survival (EFS)(From first dose until the event of interest, assessed up to 36 months after the first dose)
- Safety: Occurrence and frequency of adverse events, severity, surgical complications(From randomization to 30 days after treatment completion)
- Patient-reported outcomes: Change from European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)(Day1/21/42/63/84 of Neoadjuvant Therapy)
- Patient-reported outcomes: Change from European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13(QLQ-LC13)(Day1/21/42/63/84 of Neoadjuvant Therapy)
研究者
Wanpu Yan, MD
Associate Chief Physician
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal MetastasisNCT06971406Qiming Wang100
已完成
2 期
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma MultiformeGlioblastoma MultiformeNCT01115491Hoffmann-La Roche32
已完成
2 期
Fedratinib in Combination With NivolumabSecondary MyelofibrosisPrimary MyelofibrosisNCT05393674Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest30
已完成
2 期
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.Hodgkin LymphomaNCT02227433Fondazione Italiana Linfomi - ETS20
Unknown
2 期
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCEGFR-mutant Non-Small Cell Lung CancerNCT03904823Jiangsu HengRui Medicine Co., Ltd.58